Valuation: Inhalation Sciences Sweden AB

Market Cap 11.62M 1.21M 1.05M 974K 897K 1.69M 116M 1.73M 4.57M 56.85M 4.53M 4.43M 197M P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 8.79M 912K 798K 737K 678K 1.28M 87.77M 1.31M 3.46M 43M 3.42M 3.35M 149M EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
1 day+10.19%
1 week+1.79%
Current month-2.99%
1 month-2.16%
3 months-15.61%
6 months-47.45%
Current year-94.77%
1 week 0.2
Extreme 0.203
0.24
1 month 0.19
Extreme 0.1945
0.25
Current year 0.17
Extreme 0.172
0.58
1 year 0.17
Extreme 0.172
0.58
3 years 0.17
Extreme 0.172
4.99
5 years 0.17
Extreme 0.172
11.3
10 years 0.17
Extreme 0.172
15.48
Manager TitleAgeSince
Chief Executive Officer - 2019-09-15
Chief Tech/Sci/R&D Officer - 2004-12-31
Corporate Officer/Principal - 2025-06-01
Director TitleAgeSince
Director/Board Member - 2004-12-31
Director/Board Member 58 2025-06-23
Director/Board Member - 2024-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+10.19%+1.79%-94.77%-92.17% 1.21M
-1.97%+1.03%+28.39%+1.68% 198B
-0.58%+2.40%+7.25%-15.35% 144B
-14.15%-15.08%-33.40%-2.68% 122B
-1.32%-1.65%-57.52%-16.63% 65.44B
-2.40%-7.03%+12.08%-6.81% 49.36B
-0.11%+1.53%-23.83%-30.51% 44.74B
-3.41%-2.11%+15.33%+9.95% 37.13B
-2.44%-1.98%+28.33%+35.71% 36.23B
-1.86%-2.39%-22.85%-10.01% 28.7B
Average -1.80%-1.72%-14.10%-12.68% 72.61B
Weighted average by Cap. -3.69%-1.84%-0.99%-4.99%

Financials

2024 2025
Net sales 11.05M 1.15M 1M 926K 852K 1.61M 110M 1.65M 4.34M 54.04M 4.3M 4.21M 188M 3.04M 315K 276K 255K 235K 442K 30.36M 453K 1.2M 14.88M 1.18M 1.16M 51.65M
Net income -5.15M -534K -467K -431K -397K -748K -51.39M -767K -2.02M -25.18M -2M -1.96M -87.42M -10.16M -1.05M -922K -851K -784K -1.48M -101M -1.51M -3.99M -49.7M -3.96M -3.87M -173M
Net Debt -4M -415K -363K -335K -309K -582K -39.97M -596K -1.57M -19.58M -1.56M -1.52M -67.99M -2.83M -294K -257K -237K -218K -412K -28.27M -422K -1.11M -13.85M -1.1M -1.08M -48.08M
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5
Date Price Change Volume
26-07-17 SEK 0.2270 +10.19% 344,846
26-07-16 SEK 0.2060 -5.94% 2,301
26-07-15 SEK 0.2190 0.00% 50,571
26-07-14 SEK 0.2190 0.00% 4,200
26-07-13 SEK 0.2190 -1.79% 13,149

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISAB Stock